Rukh Lala, Nazar Halima, Usmanghani Khan
Business Development Department, Rafay Laboratories Private Limited, Karachi, Pakistan.
Research and Development Department, Herbion Pakistan Private Limited, Karachi, Pakistan.
Pak J Pharm Sci. 2016 Nov;29(6):1937-1943.
Nausea and vomiting is the common problem disturbing almost 80% of the females in initial three months of conception and later sometime throughout pregnancy. To find out the efficacy and safety of herbal coded test drug Gingocap in comparison with the control drug Pyridoxine, a randomized clinical case control study was conducted at the OPD of Yusra Medical Centre, Karachi and Amir Habib Medical Center and Maternity Home, Karachi. After administration of test and control drug the frequency of nausea and vomiting was noted after every 2 weeks on 2nd, 4th, 6th and 8th weeks during 60 days of the course of study. The percentage of reduction of nausea and vomiting symptoms from the baseline in cases treated with test Gingocap compared to control drug Pyridoxine was recorded. Overall 35 and 30 patients were administered Gingocap and Pyridoxine between 6-16 weeks conception respectively. The data analyzed through T-test using SPSS version 18.0. It was concluded that Gingocap has the potential to relieve the symptoms of nausea and vomiting and exhibited no side effects and this drug was acceptable by maximum number of the patients.
恶心和呕吐是常见问题，在怀孕的前三个月几乎困扰着80%的女性，并且在整个孕期的某些时候也会出现。为了研究草药编码试验药物金戈卡普（Gingocap）与对照药物吡哆醇相比的疗效和安全性，在卡拉奇尤斯拉医疗中心门诊部、卡拉奇阿米尔·哈比卜医疗中心和妇产医院进行了一项随机临床病例对照研究。在研究过程的60天内，在第2、4、6和8周，每2周记录一次服用试验药物和对照药物后恶心和呕吐的频率。记录了与对照药物吡哆醇相比，用试验药物金戈卡普治疗的病例中恶心和呕吐症状从基线减少的百分比。在怀孕6至16周期间，分别有35名和30名患者服用了金戈卡普和吡哆醇。使用SPSS 18.0版通过T检验对数据进行分析。得出的结论是，金戈卡普有缓解恶心和呕吐症状的潜力，且无副作用，并且该药物为大多数患者所接受。
